In acute promyelocytic leukemia (APL) the retinoic acid receptor alpha (RARa) becomes an oncogene through the fusion with several partners, mostly with promyelocytic leukemia protein (PML), all of which have in common the presence of a self-association domain. The new fusion proteins, therefore, differently from the wild-type RARa, which forms only heterodimers with retinoic X receptor alpha, are also able to homooligomerize. The presence of such a domain has been suggested to be crucial for the leukemogenic potential of the chimeric proteins found in APL blasts. Whether or not any selfassociation domain is sufficient to bestow a leukemogenic activity on RARa is still under investigation. In this work, we address this question using two different X-RARa chimeras, where X represents the coiled-coil domain of PML (CC-RARa) or the oligomerization portion of the yeast transcription factor GCN4 (GCN4-RARa). We demonstrate that in vitro both proteins have transforming potential, and recapitulate the main PML-RARa biological properties, but CC-RARa is uniquely able to disrupt PML nuclear bodies. Indeed, in vivo only the CCRARa chimera induces efficiently APL in a murine transplantation model. Thus, the PML CC domain represents the minimal structural determinant indispensable to transform RARa into an oncogenic protein.
Introduction
Acute promyelocytic leukemia (APL) is clinically characterized by the accumulation of blast cells in the bone marrow, which failed to accomplish proper myeloid differentiation program, thus becoming blocked at the promyelocytic stage.
1,2 At a molecular level, it is etiologically linked to a balanced chromosomal translocation involving genes encoding for the retinoic acid receptor alpha (RARa) and, in most cases, the promyelocytic leukemia protein (PML). 3, 4 Less frequent partners involved in the APL-related translocations comprise promyelocytic leukemia zinc-finger gene, 5 nucleophosmin, 6 nuclear mitotic apparatus 7 and signal transducer and activator of transcription 5b. 8 The oncogenic PML-RARa (PR) fusion protein behaves as an altered RAR, with an expanded repertoire of DNA-binding sites, 9 and acts as a constitutive repressor of retinoic acid (RA) target genes because of an aberrant recruitment of chromatin modifying enzymes (that is, histone deacetylases, 10, 11 histone methyltransferases 12 and DNA methyltransferases 13 ). These chromatin changes subvert the normal gene expression pattern thus altering cell transcriptional state and enhancing the self-renewal property of PR-expressing cells. Noteworthy, all of the proteins that fuse to RARa contain a selfassociation motif that is faithfully conserved in the translocated versions. 14 The transforming activities ex vivo of APL-related fusions are strictly dependent on the presence of an oligomerization interface. [15] [16] [17] In the case of PR, the PML coiled-coil (CC) domain, which is part of the ring-B box-CC/tripartite motif, 18 constitutes the interacting surface responsible for the formation of PR high molecular weight [19] [20] [21] complexes that are essential for PR transforming properties. 20 Oligomerized forms of RARa are able to recapitulate at a various extent, in vitro, the main biological properties of PR: nonetheless, to date, none of the described artificial RARa oligomers succeeded in triggering efficiently leukemia in vivo. 15, 16, 20, 22, 23 In this study, we demonstrate that the CC domain of PML, but not a heterologous oligomerization domain, behaves as the minimal structural determinant able to confer a full leukemogenic potential to RARa in vivo.
Materials and methods

Cell lines
Murine hematopoietic 32D cells were grown in RPMI supplemented with interleukin (IL)-3, 10% fetal bovine serum, 2 mM L-glutamine and antibiotics. Phoenix cell lines were purchased from ATCC (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics. Cultures were maintained in a humidified tissue culture incubator at 37 1C in 5% CO 2 .
Purification and manipulation of Lin-cells
Lineage minus (Lin-) cells were purified from 129Sv mice and maintained as previously described.
1 After 3 days, cells were infected with the viral supernatant collected from transfected packaging ecotropic Phoenix cells expressing PR, CC-RARa (CCR) and GCN4-RARa (GCR), and then sorted by means of green fluorescent protein (GFP) positivity. 1 
Expression vectors
For retroviral infection of hematopoietic progenitors, the complementary DNA encoding for PR, CCR and GCR fusion proteins were cloned into the PINCO vector (EcoRI site). 24 PR retroviral construct has been previously described. 10 The CC domain of PML 19 and the sequence encoding for the pIIGCN4 trimeric peptide 25, 26 were obtained by polymerase chain reaction (PCR) amplification and fused to RARaA -gene, 27 through an EcoRV site present upstream of the RARaA -sequence. For the immunoprecipitation experiments the following expression vectors were used: PCDNA3/PR, PCDNA3/PML-FLAG, PSG5/CCR and PSG5/GCR.
Immunofluorescence
Lin-cells were transduced with retroviral vectors encoding for PR, CCR and GCR fusion proteins as previously described. 1 Three days after infection, the cells were sorted for GFP positivity and plated in methylcellulose medium. After 10 days, cells were harvested, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton-X and blocked with 5% normal goat serum. Staining was performed using a mouse monoclonal anti-PML antibody (clone 36.1-104, CHEMICON International, Inc., Temecula, CA, USA). A Cy3-conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was used as secondary antibody.
Immunoblot
Whole cell extracts from 300 000 GFP-positive sorted Lin-cells were obtained from direct lysis in sodium dodecyl sulfate (SDS) sample buffer (50 mM Tris HCl, 10% glycerol, 2% SDS, 5% b-mercaptoethanol, 0.01% bromophenolblue). Proteins were separated by SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membrane and probed with a rabbit polyclonal anti-RAR antibody (C-20 sc-551, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Co-immunoprecipitation
Phoenix cells were transiently transfected (calcium phosphate method) with the required expression plasmids. At 48 h after transfection, cells were harvested and lysed in E1A buffer (50 mM Hepes, 250 mM NaCl, 1% NP-40 added with 100 mg/ml phenylmethylsulfonyl fluoride and 1 mg/ml aprotinin and leupeptin). The cell suspension was briefly sonicated and incubated on ice. The lysates were then clarified by centrifugation. The sovranatant was quantified with the Bradford method and 5 mg were subjected to immunoprecipitation with an anti-FLAG antibody directly conjugated to protein A sepharose beads (to immunoprecipitate PML protein). After overnight incubation at 4 1C beads were washed three times with ice-cold lysis buffer, resuspended in SDS Laemmli buffer and boiled to allow the detachment of the bound proteins. Eluates were analyzed by gel electrophoresis. Western blot analysis was performed using an anti-RAR antibody (RARa C-20 sc-551 Santa Cruz Biotechnology, used at 400 ng/ml) or an anti-FLAG antibody.
Differentiation and serial replating assays
A total of 5000 sorted Lin-cells were plated in methylcellulose (Stem Cell Technology, Vancouver, BC, Canada) medium containing fetal calf serum, stem cell factor, IL-3, IL-6, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. After 7-10 days of culture, the Lin-derived colonies were scored and the cells used for immunolabeling, serial replating experiments and morphological analysis as described previously. 1 
In vivo transplantation studies
Lethally irradiated 129Sv mice, 12-to 24-week old, were injected with 300 000 GFP-positive Lin-cells transduced with the experimental constructs 1 and monitored for clinical signs of leukemia (by inspection, and periodical blood analysis using the AcT 5diff Beckman Coulter, Brea, CA, USA). Quantitative PCR experiments were performed on total genomic DNA (25 ng) extracted from peripheral blood (DNeasy Blood and Tissue Kit, Qiagen, Valencia, CA, USA) to control the long-term reconstitution of the hematopoietic compartment. The following primers were used: murine Nucleolin (used for normalization of genomic DNA): forward 5 0 -GGCGTGGTGACTCCACGT-3 0 ; reverse 5 0 -CGAAATCACCTCTTAAAGCAGCA-3 0 ; and human RARa: forward 5 0 -GCCATCTGCCTCATCTGC-3 0 ; reverse 5 0 -TCCGCACGTAGACCTTTAGC-3 0 . All procedures involving animals were done in accordance with national and international laws and policies.
Immunophenotyping and histopathological analysis
Fluorescence-activated cell sorting analysis (BD, FACSCantoII BD, FACSDiva Software, Becton Dickinson, Franklin Lakes, NJ, USA) for the characterization of leukemias was performed on splenocytes derived from leukemic mice (with a leukemic infiltration 480%). The antibodies used for the immunophenotyping were: Ly-6A/E (SCA1) PE-Cy5.5 conjugated, CD117 (C-Kit) APC conjugated, CD11b (MAC1), Ly-6G (Gr-1), CD3e, CD45R (B220) all PE-Cy7 conjugated (eBioscience, San Diego, CA, USA). Blood smears and cytospins were stained by May-Grünwald-Giemsa (Sigma-Aldrich, St Louis, MO, USA).
Quantitative PCR
Total RNA was purified using RNeasy Mini Kit (Qiagen), quantified and reverse transcribed. In all, 5 ng of complementary DNA were used to perform quantitative PCR using SYBR Green Reaction Mix (Perkin Elmer, Boston, MA, USA). In order to detect RAR fusion transcripts the following primers, designed on human RAR, were used: forward 5 0 -GCCATCTGCCTC ATCTGC-3 0 and reverse 5 0 -TCCGCACGTAGACCTTTAGC-3 0 . Values were normalized against murine GAPDH mRNA:
Size exclusion chromatography (SEC)
SEC was performed as previously described. 20 Briefly, 32D cells were transduced with retroviral vectors encoding for the chimeric proteins, and sorted for GFP positivity 48 h post infection. Whole cell lysates were obtained using modified RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.2% SDS, 2 mM EDTA, 5 mM NaF, aprotinin and leupeptin 10 mg/ml, pepstatin 2 mg/ml, 1 mM phenylmethylsulfonyl fluoride and 100 mM Tris-Cl [pH 7.4] ). In all, 1 mg of total extract was used to perform SEC analysis using a Superose 6 HR 10/30 column (Pharmacia Biotech, Piscataway, NJ, USA). The resulting fractions were analyzed by SDS-polyacrylamide gel electrophoresis followed by immunoblot using an anti-RAR antibody.
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Results and Discussion
The presence of a self-association domain in all of the translocation products responsible for the occurrence of APL represents a hallmark of this type of cancer.
14 Taking PR as a working model, we explored the oncogenic potential of two artificial constructs containing the same RARa segment that is usually present within all of the natural APL-related chimeric oncogenes, fused to either a homologous (PML derived) or a heterologous oligomerization domain. In particular, we used the CC domain of PML, 18 and the GpII mutagenized peptide derived from the yeast GCN4 transcription factor able to induce protein trimerization 25 (Figure 1a) , which was shown to occur also for the isolated recombinant CC of PML. 20 Self-association drives the ability of PR to form high molecular weight complexes detectable in SEC assays. 19, 20 Therefore, we analyzed the oligomerization properties of our experimental constructs in SEC experiments. Both CCR and GCR showed the ability to form high molecular weight complexes, similarly to PR (Figure 1b) . The prevalence of these complexes in all of the three chimeras, and the absence of low molecular weight monomeric forms, indicate that all the fusion proteins exist as oligomeric forms.
With the use of the described RARa mutants, we tried to uncouple the oligomerization activity from any specific biological function conferred by the homologous self-association motif The coiled-coil domain of PML drives leukemogenesis M Occhionorelli et al derived from PML, unraveling the relative contribution played by the different portions of PR during APL development. At first, we evaluated the ability of the two experimental constructs to physically interact with PML and to disturb the architecture of NBies. For this purpose, cells expressing the different proteins were analyzed by immunoprecipitation and immunofluorescence. As shown in Figure 2a , transiently transfected CCR and PR co-immunoprecipitated with the tagged version of PML (PML-FLAG), revealing a direct interaction between these proteins. 27 On the contrary, GCR did not associate with PML-FLAG, confirming that the association of PML with PR requires the CC region of PML. 27 To evaluate the impact of the fusion proteins on NBies organization, we performed an immunofluorescence analysis in hematopoietic murine progenitors (Lin-cells) transduced with viral vectors encoding for the various chimeras. Both PR and CCR were able to affect morphology of endogenous NBies, with the disaggregation of the PML dots into a fine granular pattern, which became almost invisible, as previously described for murine PML on expression of PR (Figures 2b and c) . 16 On the contrary, expression of GCR had no detectable effects on NBies organization (Figures 2b and c) , suggesting that the disruption of NBies architecture occurs through the direct binding of the chimeric proteins to PML (consistently with the co-immunoprecipitation experiments).
To further dissect the biological activity of these chimeras, on the expression of CCR and GCR in murine hematopoietic progenitor Lin-cells, 1 we assayed their ability to block myeloid differentiation and to support serial replating (indicative of enhanced proliferative potential) in methylcellulose assay.
RNA analysis showed that all chimeric genes were expressed at a similar level (Figure 3a) . At the protein level, while CCR and GCR were expressed similarly, PR was expressed at lower levels (that is expected, because it is toxic at high levels and selects for low levels of expression in primary progenitors 28 ) and showed multiple bands because of post-translational modifications 29 ( Figure 3b ). Both CCR and GCR induced a consistent differentiation block, similarly to PR (Figures 3c and d) . Morphological analysis of PR CCR-and GCR-transduced cells revealed the presence of cells with immature features, compared with control cells clearly differentiated along the myeloid lineage (macrophages and granulocytes: Figure 3d ). In addition, immunophenotypical analysis of the same cells showed a strong decrease in Mac-1 differentiation marker (Figure 3c) .
To address the influence of the chimeric proteins on the proliferative potential of hematopoietic progenitors, we performed serial replating experiments. Although control cells exhausted their proliferative potential after a few platings, both CCR and GCR dramatically increased the colony-forming potential, which lasted for at least eight platings, similarly to PR, and that is considered indicative of acquired transforming ability in vitro (Figure 4a) . 17, 29 Recently, in APL leukemic cells a sub-population enriched in leukemia-initiating cells has been identified, which showed simultaneous expression of more The coiled-coil domain of PML drives leukemogenesis M Occhionorelli et al mature differentiation markers (such as, Gr1), and stem cell markers (such as, c-Kit). 30, 31 Indeed, PR, CCR and GCR cells recovered from the third plating showed the co-expression of c-Kit/Gr-1 markers (Figure 4b) . 1 Taken together, these results indicate that all chimeric proteins showed a similar biological response in vitro, though GCR was unable to interact with PML and disrupt endogenous NBies.
Finally, we tested the in vivo leukemogenic potential of the RARa fusion proteins. For this purpose, Lin-cells transduced with retroviral vectors encoding for the chimeric proteins were injected into lethally irradiated recipient mice.
1 Peripheral blood of the transplanted animals was analyzed to verify the long-term reconstitution of the hematopoietic compartment and monitored periodically in order to check for APL development. Strikingly, although both GCR and CCR were able to reconstitute recipient mice, only CCR was able to induce leukemia with a median latency very similar to that obtained expressing PR (156 and 154 days, respectively) (Figure 5a ). GCR-expressing mice, as control mice transplanted with cells transduced with the empty vector, did not develop leukemia for the entire duration of the experiment (4400 days) (Figure 5a ). Leukemias arisen from CCR transplanted mice were characterized immunophenotypically and morphologically (Figures 5b and c) revealing an APL-like phenotype. We observed: (a) splenomegaly and hepatomegaly because of the accumulation of blast cells with promyelocytic features in the infiltrated organs and (b) the presence of a cell subpopulation aberrantly co-expressing the c-Kit and Gr-1 surface markers (Figure 5b) . 1 Overall these results indicate that although an oligomerized form of RARa is sufficient in vitro to recapitulate the main oncogenic properties of PR, (that is, differentiation block and enhanced proliferative potential), in vivo additional functions are necessary to trigger a full leukemic phenotype.
These results confirm and extend previous studies, aimed to investigate the role of RAR oligomerization in leukemogenesis. 15, 16, 22, 23, 29 Using a novel heterologous oligomerization domain (a mutagenized GCN4-derived peptide, to obtain trimeric proteins that mimic those formed by the CC of PML in vitro), we reproduce the finding that RAR oligomerization per se is sufficient to yield a chimeric protein able to: (a) block myeloid differentiation; and (b) enhance proliferative potential of hematopoietic progenitors. We now show that GCR is also able (as PR and CCR) to induce the progressive in vitro expansion of a cell sub-population co-expressing myeloid maturation markers (Gr-1) and more primitive markers (c-Kit), which becomes prominent in frank APL in vivo, 1, 32, 33 and that resembles a sub-population enriched in leukemia-initiating cells in APL. 30, 31 Surprisingly, the acquisition of these in vitro properties is not sufficient to drive leukemogenesis in vivo, and GCR (as other chimeric constructs tested before: see Sternsdorf et al. 16 ) did not induce APL in transplanted mice. Interestingly, the leukemogenic potential of these chimeric RAR oligomers has been shown previously to be unveiled by co-expression of an activated cytokine receptor: 16 as in vitro culture conditions require the use of several cytokines in the The coiled-coil domain of PML drives leukemogenesis M Occhionorelli et al culture medium, it is possible that altered signaling pathways because of those artificial growth conditions (mimicked in vivo by the mutated receptor) are able to complement the defect in oncogenic properties present in these constructs, compared with naturally occurring PR. The common feature of these defective chimeric constructs is that, while leading to RAR oligomerization, they are unable to interact with PML, and do not disrupt NBies. It appears therefore that the lack of interference with PML-mediated pathways may be fundamental to achieve full oncogenic conversion of RAR oligomers. Indeed, leukemias induced by the full-length PR oncogene are accelerated in PMLÀ/À mice. 34 It has been shown, however, that RAR oligomerization per se in a PMLÀ/À background is not sufficient to drive APL in vivo, 16 thus suggesting that gain-of-function by RAR oligomers able to interfere actively with PML pathways may be a necessary alteration to drive leukemogenesis.
The CCR construct presented here ideally completes these studies, showing indeed that addition to RAR of a selfassociation interface derived from the endogenous PML, and therefore able to associate with PML (andFin the context of CCRFto disrupt NBies), is sufficient to convert efficiently RAR into an oncogene. Indeed, previous articles have already shown that PML is involved in the regulation of the oncosuppressor p53 35 and in the maintenance of hematopoietic stem cell pool, 36 arguing that the misregulation of these activities could clearly trigger transformation of primary hematopoietic cells. CCR is proficient in all of the biochemical and biological properties tested, similarly to PR, and is the first oligomerization interface shown to drive leukemogenesis in vivo at levels comparable to PR. It would be of interest to study the behavior of CCR also in a PMLÀ/À background: we hypothesize thatFas PRFit would still behave as an oncogenic, gain-of-function mutant, irrespective of the presence of wild-type PML.
The complexity of PML-associated functions, however, might be higher than expected, and not only related to its ability to mediate self-association. Within the PML B-BOX domain (absent in GCR and CCR), a K160 sumoylation site mediates DAXX recruitment and transcriptional repressive activity, necessary to block myeloid differentiation and enhance proliferative potential in vitro, and to transform hematopoietic progenitors in vivo. 29 Strikingly, the defective K160R PR mutant is able to disrupt NBies and to form oligomers, showing that these two activities are not sufficient to mediate the oncogenic properties of RAR fusion protein either in vivo and in vitro. It is tempting to speculate that sumoylation is required to counteract (through DAXX recruitment) additional functions of PML (for example, recruitment of co-activators such as p300/CBP) that cannot be recruited by the isolated CCR (or in GCR, and other artificial RAR oligomers).
Our study further points to the exquisite selectivity in the choice of oncogenic fusion partners in APL (and possibly other leukemias): the demonstration that the isolated CC is indeed the minimal structural determinant required to obtain APL in vivo can now lead to further investigations to unravel the biochemical pathways involved in imposing a fully transforming activity to the oncogenic fusion protein. The coiled-coil domain of PML drives leukemogenesis M Occhionorelli et al
